---
title: "Insulet Closes $450 Million Senior Notes Issuance"
description: "Insulet Corporation has successfully closed its issuance of $450 million in 6.50% Senior Notes due 2033, with net proceeds of approximately $444 million. The company also amended its Credit Agreement,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232743497.md"
published_at: "2025-03-21T12:22:38.000Z"
---

# Insulet Closes $450 Million Senior Notes Issuance

> Insulet Corporation has successfully closed its issuance of $450 million in 6.50% Senior Notes due 2033, with net proceeds of approximately $444 million. The company also amended its Credit Agreement, extending revolving credit commitments to March 20, 2030, and increasing them to $500 million. Additionally, Insulet repurchased $419 million of its Convertible Senior Notes due 2026, affecting its outstanding debt. Insulet specializes in innovative insulin delivery systems, including the Omnipod Insulin Management System, and currently has a market cap of $18.29 billion.

An announcement from Insulet ( (PODD) ) is now available.

On March 20, 2025, Insulet Corporation closed its issuance and sale of $450 million in 6.50% Senior Notes due 2033, with net proceeds expected to be approximately $444 million. Additionally, Insulet entered into a Seventh Amendment to its Credit Agreement, extending the maturity of revolving credit commitments to March 20, 2030, and increasing the commitments to $500 million. The company also engaged in Note Repurchase Transactions, repurchasing $419 million of its Convertible Senior Notes due 2026, which will impact its outstanding debt and potentially influence stock market activities.

**More about Insulet**

Insulet Corporation operates in the medical device industry, primarily focusing on the development and sale of innovative insulin delivery systems. The company is known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump for individuals with diabetes.

**YTD Price Performance:** 3.49%

**Average Trading Volume:** 668,750

**Technical Sentiment Consensus Rating:** Sell

**Current Market Cap:** $18.29B

For detailed information about PODD stock, go to TipRanks’ Stock Analysis page.

## Trending Articles:

-   NVO Lawsuit Alert! Class Action Lawsuit Against Novo Nordisk A/S
-   Micron Stock Remains Attractive with Strong AI Demand, Says Mizuho and Hikes PT
-   Nvidia Ventures into the Quantum Computing Space with New Lab in Boston

Questions or Comments about the article? Write to editor@tipranks.com

### Related Stocks

- [PODD.US - Insulet](https://longbridge.com/en/quote/PODD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Insulet Reports Fourth Quarter and Full Year 2025 Results | Insulet Corporation reported a 31% revenue increase for Q4 2025, totaling $783.8 million, and a full-year revenue of $2. | [Link](https://longbridge.com/en/news/276225615.md) |
| Alberta Investment Management Corp Takes Position in Insulet Corporation $PODD | Alberta Investment Management Corp acquired a new stake in Insulet Corporation (NASDAQ:PODD) during Q3, purchasing 14,50 | [Link](https://longbridge.com/en/news/276426682.md) |
| MannKind (MNKD) Valuation Check As Afrezza Pediatric Milestones Open Needle Free Insulin Opportunity | MannKind (MNKD) has enrolled its first pediatric patient in the INHALE-1ST Afrezza study, potentially leading to the fir | [Link](https://longbridge.com/en/news/276150484.md) |
| Insulet Corporation (NASDAQ:PODD) Given Average Rating of "Moderate Buy" by Analysts | Insulet Corporation (NASDAQ:PODD) has received an average rating of "Moderate Buy" from 24 analysts, with 20 recommendin | [Link](https://longbridge.com/en/news/276105237.md) |
| Insulet Corporation highlights diabetes management leadership and market growth in new investor presentation | Insulet Corporation showcased its leadership in diabetes management at the J.P. Morgan 44th Annual Healthcare Conference | [Link](https://longbridge.com/en/news/272454304.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.